Notably, 3 months after completion of the 2-dose regimen (day 115), the cytokine profiles diverged into distinct clusters, with profiles of patients with IBD coinciding with regions defined by higher levels of IL-10, IFN-γ, and IL-2. This evidence concerns the gene IL2 and inflammatory bowel disease.